Lung-RADS System May Reduce Rate of False-Positives

Share this content:
Lung-RADS can reduce false-positive rate for lung cancer screening.
Lung-RADS can reduce false-positive rate for lung cancer screening.

Use of the American College of Radiology Lung Imaging Reporting and Data System (Lung-RADS) classification system for low-dose computed tomography (LDCT) can reduce the false-positive result rate but also decreases sensitivity, according to a study published in the Annals of Internal Medicine.

Paul F. Pinsky, Ph.D., from the National Cancer Institute in Bethesda, Md., and colleagues conducted a retrospective assessment to apply the Lung-RADS criteria to the National Lung Screening Trial (NLST). 

Participants, aged 55 to 74 years, with at least a 30-pack-year smoking history, and who were current smokers or had quit in the past 15 years, were randomized to the LDCT group of the NSLT. They underwent three annual LDCT lung cancer screenings.

Of the 26,722 participants, 26,455 received a baseline screen and 48,671 screenings were performed after baseline.

The researchers found that the false-positive result rate for Lung-RADS was 12.8 percent at baseline, compared with 26.6 percent for the NLST; after baseline, the false-positive result rates were 5.3 and 21.8 percent, respectively.

RELATED: Bevacizumab Safe for Non-Small Cell Lung Cancer, Asymptomatic Brain Metastases

Baseline sensitivity was 84.9 and 93.5 percent for Lung-RADS and NLST, respectively; after baseline, the sensitivities were 78.6 and 93.8 percent, respectively.

"Lung-RADs may substantially reduce the false-positive result rate; however, sensitivity is also decreased," the authors write. "The effect of using Lung-RADs criteria in clinical practice must be carefully studied."


  1. Pinsky, Paul F., PhD, et al. "Performance of Lung-RADS in the National Lung Screening Trial: A Retrospective Assessment." Annals of Internal Medicine. doi:10.7326/M14-2086. February 10, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs